PHA2022 Chap.4 Drug Benefit, Harm and Society
Drug Benefit, Harm and Society
Drug policy and public communication require translation from measured outcomes to population consequences. Begin with the decision: approve, restrict, subsidise, warn, monitor, decriminalise or provide harm reduction. Name whose outcomes count, the time horizon and the comparison.
Evidence cannot decide a value trade-off that has not been stated.
Absolute risk is the probability of an outcome in a defined group and period. Relative risk compares risks between groups. A 50% relative reduction means very different absolute benefit when baseline risk is 40% versus 2%.
Number needed to treat or harm can aid communication but inherits the study population, follow-up and outcome definition.
Association between drug exposure and harm can be confounded by indication, severity, co-use, access and behaviour. Randomised trials address some questions but may be infeasible or unethical for harmful exposures.
Cohort, case-control, interrupted time-series and natural-experiment designs contribute different evidence. Strong policy arguments combine designs and state which alternatives remain.
Benefit and harm distributions matter. An average benefit can conceal a subgroup with little benefit or high harm.
Rare severe adverse events may not appear before wide use, so pharmacovigilance and reporting extend evidence after approval. Detection signals require investigation because reporting patterns, publicity and exposure counts affect raw case numbers.
Harm reduction accepts that immediate elimination of use may not be feasible and targets preventable consequence.
Examples can include accurate information, sterile equipment, overdose reversal, supervised care or safer prescribing, depending on evidence and setting. Evaluate actual outcomes rather than treating harm reduction as endorsement or abstinence as the only measurable success.
Regulation changes incentives and can produce unintended consequences.
Restricting one product can shift use to another; criminalisation can alter purity, stigma and help-seeking; access controls can protect some people while burdening those with legitimate need.
Map the behavioural pathway through which the policy is expected to work and specify indicators of displacement or inequity.
Worked headline: a cohort reports a relative risk of 2.0 for a rare adverse outcome, increasing estimated risk from 1 to 2 per 10,000 over one year. Relative doubling is accurate, but the absolute increase is 1 per 10,000 in that population.
Communication should include uncertainty, confounding, severity and who was represented rather than choosing only the more dramatic expression.
Controversy projects need a charitable account of competing positions. Separate empirical disagreement from value disagreement and implementation concern. A stakeholder may accept the same efficacy estimate but weight autonomy, cost or distribution differently.
Present the strongest evidence for each material claim and say what new evidence would change the recommendation.
For public-facing work, define dose, route, population and outcome; distinguish prescribed use from nonmedical patterns where relevant; and avoid stigmatising language. A balanced conclusion can still recommend action.
Balance means representing material benefit, harm and uncertainty proportionally, not giving weak claims equal weight.
Causal policy evaluation needs a counterfactual: what would outcomes have been without the change? Simple before–after comparison can confuse the policy with trends, publicity, product reformulation or simultaneous services.
Interrupted time series examines level and slope, controlled series adds a comparison, and natural experiments exploit differential exposure. Check anticipation, spillover and measurement changes.
A policy claim is strongest when several designs predict the same direction through a plausible implementation mechanism.
A recommendation is complete only when it names an implementation indicator, an equity consequence and an observation that would trigger revision.
What this chapter covers
- 01
absolute risk
- 02
relative risk
- 03
harm reduction
- 04
evaluate drug-related claims across individual effect, population risk, regulation, equity and unintended consequence
- 05
Evidence of average effect does not decide policy without population, distribution, feasibility and value judgements.
Translate a risk headline
- 1State baseline risk.
- 1State absolute change.
- 1State relative change.
- 1Describe population and follow-up.
- 1Add uncertainty and severity.
Key terms
- absolute risk
- The probability of an outcome in a defined population and time period.
- relative risk
- The ratio of outcome risk between compared groups.
- harm reduction
- Policies or practices intended to reduce adverse consequences without requiring immediate elimination of all use.
Drug Benefit, Harm and Society FAQ
What is the main reasoning task?
Evaluate drug-related claims across individual effect, population risk, regulation, equity and unintended consequence.
What boundary matters?
Evidence of average effect does not decide policy without population, distribution, feasibility and value judgements.
Are these official questions?
No. They are original AskSia practice aligned to the recovered 2026 unit.
How should I revise drug reasoning?
Draw the mechanism, work a changed dose, exposure, context or design, and state what evidence would reverse the conclusion.
Exam move
Retrieve the target or decision, trace concentration and time, work one changed case, then write the translational boundary.
Working through Drug Benefit, Harm and Society in PHA2022? Sia is AskSia’s AI Pharmacology tutor — ask any PHA2022 Drug Benefit, Harm and Society question and get a clear, step-by-step explanation grounded in how PHA2022 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
